Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Tracking differential growth of secondary liver metastases is important for early detection of progression but remains challenging due to variable tumor growth rates. We aimed to automate accurate, consistent, and efficient longitudinal monitoring.

Methods: We developed an automatic 3D segmentation and tracking algorithm to quantify differential growth, tested on contrast-enhanced MRI follow-ups of patients with neuroendocrine liver metastases (NELMs). The output was integrated into a decision support tool to distinguish between progressive disease, stable disease, and partial/complete response. A user study involving an expert group of seven expert radiologists evaluated its impact. Group comparisons used the Friedman test with post hoc analyses.

Results: Our algorithm detected 991 metastases in 30 patients: 13% new, 30% progressive, 18% stable, and 18% regressive; the remainder were either too small to measure (15%) or merged with another metastasis in the follow-up assessment (6%). Diagnostic accuracy improved with additional information on hepatic tumor load and differential growth, albeit not significantly ( = 0.72). The diagnosis time increased ( < 0.001). All radiologists found the method useful and expressed a desire to integrate it in existing diagnostic tools.

Conclusions: We automated segmentation and quantification of individual NELMs, enabling comprehensive longitudinal analysis of differential tumor growth with the potential to enhance clinical decision-making.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12383499PMC
http://dx.doi.org/10.3390/bioengineering12080874DOI Listing

Publication Analysis

Top Keywords

liver metastases
12
differential growth
12
follow-up assessment
8
contrast-enhanced mri
8
tumor growth
8
growth
5
automatic tracking
4
tracking liver
4
metastases
4
metastases follow-up
4

Similar Publications

Introduction: Pancreatic adenocarcinomas (PDAC) have a poor prognosis, with a 5-year relative Survival rate of 11.5%. Only 20% of patients are initially eligible for resection, and 50% of patients presented with metastatic disease, currently only candidates' palliative treatment.

View Article and Find Full Text PDF

Purpose: To build computed tomography (CT)-based radiomics models, with independent external validation, to predict recurrence and disease-specific mortality in patients with colorectal liver metastases (CRLM) who underwent liver resection.

Methods: 113 patients were included in this retrospective study: the internal training cohort comprised 66 patients, while the external validation cohort comprised 47. All patients underwent a CT study before surgery.

View Article and Find Full Text PDF

Given the limited diagnostic technologies and treatment options available for lung adenocarcinoma (LUAD) patients with liver metastases, it is crucial to identify potential genomic signatures associated with liver metastasis, which could significantly contribute to the development of improved diagnostic tools and treatment strategies for LUAD patients with liver metastases. In this study, we identified specific genetic alterations in tumor samples with liver metastases by targeted capture sequencing. The results showed that the significantly higher mutation frequencies of , and in LUAD patients with liver metastases and and mutations found in both tumor tissues and plasma samples from patients with liver metastases.

View Article and Find Full Text PDF

Efficacious suppression of primary and metastasized liver tumors by polyIC-loaded lipid nanoparticles.

Hepatology

September 2025

Department of Pathology, Department of Molecular Biology, Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA.

Background And Aims: So far, there is no effective mechanism-based therapeutic agent tailored for liver tumors. Immune checkpoint inhibitors (ICIs) have demonstrated limited efficacy in liver cancer, often associated with severe adverse effects. Although poly-inosinic:cytidylic acid (polyIC) has shown an adjuvant effect when combined with anti-PD-L1 antibody (αPD-L1) in treating liver tumors in animal models, its systemic toxicity limits its clinical utility.

View Article and Find Full Text PDF

Rapid Metastatic Growth of A Pancreatic Signet Ring Cell Carcinoma within 6 weeks of A Negative CT.

Eur J Case Rep Intern Med

August 2025

Division of Gastroenterology, Department of Medicine, Staten Island University Hospital, Northwell Health, Staten Island, USA.

Unlabelled: Pancreatic signet ring cell carcinoma (PSRCC) is a rare and aggressive subtype of pancreatic cancer with a dismal prognosis. We present the case of a 50-year-old male who, within six weeks, developed a pancreatic mass with liver metastases. Endoscopic ultrasound-guided biopsy confirmed PSRCC.

View Article and Find Full Text PDF